OpenAI President says AI could make death optional in 18 months

A shift in medical expectations

Greg Brockman, the co-founder and president of OpenAI, recently shared a bold vision for the future of human health. Speaking at a WSJ Tech event, he suggested that the rapid progress of artificial intelligence is nearing a turning point for medicine. He believes the technology is moving from theoretical promises to actual delivery in the near term.

Brockman noted that while the idea of AI curing diseases has been a common trope since the launch of ChatGPT, the reality is changing quickly. He expects to see significant strides and impacts on biology and health over the next year and a half. This timeframe represents a shift from long-term research to immediate, tangible results.

The core of his argument rests on the idea that AI can process biological data at a scale humans cannot match. By accelerating these processes, Brockman believes we are approaching a point where the fundamental nature of human mortality might change. He stated that the question of thinking about death could eventually become a choice.

The longevity movement

Brockman is not alone in his optimism regarding the intersection of AI and human longevity. Other prominent figures in the tech space are making similar claims about the end of incurable conditions. For instance, futurist Peter Diamandis has pointed toward 2030 as a major turning point for how long humans can live.

Diamandis uses the term "longevity escape velocity" to describe a convergence of AI-driven technologies. He advises people to survive long enough to benefit from these upcoming advancements while avoiding avoidable risks. This philosophy suggests that the goal is to reach a point where technology extends life faster than time can take it away.

Similarly, biohacker Bryan Johnson has argued that AI could mean no medical condition is ever presumed to be incurable again. These perspectives reflect a growing belief among tech leaders that the human body is a system that can be reprogrammed. They view aging not as an inevitability, but as a technical hurdle that AI is uniquely suited to solve.

Skepticism and social trends

Despite the optimism, some observers are wary of the intensity surrounding these predictions. Shyam Sankar, the chief technology officer at Palantir, recently highlighted a unique phenomenon among AI researchers. He noted that some are so convinced AI will cure cancer that they have even changed their personal habits, like smoking, as a result.

Sankar described this level of belief as a "kind of this mass psychosis social delusion." His comment suggests that the hype surrounding AI's ability to rewrite human biology might be reaching an extreme level. It highlights a divide between the technical possibilities of the software and the psychological state of the people building it.

This tension exists because the technology is still in its early stages of medical application. While the hype is significant, the actual results are still being tested in clinical settings. The conversation serves as a reminder of the profound influence that high-level tech goals can have on public perception and individual behavior.

Current evidence and progress

The potential for AI to impact biology is not entirely theoretical, as several recent developments provide context. For example, an AI-developed drug recently appeared in a clinical trial with the goal of making patients biologically younger. This represents a direct application of machine learning to the problem of human aging.

Other examples of AI's capabilities include its ability to handle complex coding tasks and solve difficult mathematical problems. The co-founder of CentOS recently built a Linux-compatible kernel in just 11 days, with AI handling most of the coding. These milestones demonstrate the speed at which AI can execute complex instructions across different fields.

Even when AI fails to solve a specific problem, it often provides unexpected insights. Anthropic’s Claude model recently attempted to solve the Riemann hypothesis, a long-unproven math problem. While it did not crack the hypothesis, it produced an unexpected new finding during the process. These instances show that AI is already finding new paths in science and engineering.

The road ahead for AI

As AI giants make these grand pronouncements, they are simultaneously navigating a complex landscape of regulation and risk. The technology presents a dual reality of immense opportunity for human advancement and potential landmines that could damage society. The conversation around longevity is just one facet of how AI is being positioned as a tool for fundamental change.

Elon Musk has also weighed in on the biological side of this discussion, noting that the human body ages as a synchronized system. He argues that because we do not have parts of our bodies age at different rates, the programming of our biology must be addressed as a whole. He suggests that this programming could be changed to allow humans to live significantly longer.

The next few years will determine whether these predictions move from the realm of tech-optimism into clinical reality. As AI continues to integrate with biology and health, the focus will shift toward the safety and accessibility of these breakthroughs. The transition from "optional death" to a medical reality remains one of the most ambitious goals in modern technology.